Hospital
Inova Health Care Services
Inova Health Care Services was paid $69.02M by Medicaid between Jan 2018 and Dec 2024, across 321 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoINOVA HEALTH CARE SERVICES
ALEXANDRIA, VA 22304
ALEXANDRIA, VA 22304
33aNPI1255684460assigned 10/25/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$69.02M
24GClaims1,306,260
24DCodes billed321
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#8 of 80
Median peer was paid$14.69M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 133,409 | $4.75M | |
| 2019 | 191,646 | $7.76M | |
| 2020 | 152,402 | $7.03M | |
| 2021 | 182,933 | $8.58M | |
| 2022 | 197,771 | $11.08M | |
| 2023 | 228,711 | $14.56M | |
| 2024incomplete | 219,388 | $15.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 71,915 | 62,556 | $13.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 52,329 | 45,004 | $10.87M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 24,767 | 19,427 | $8.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 20,757 | 18,080 | $4.37M |
| G0378 | Hospital observation service, per hour | 4.3% | 14,372 | 11,469 | $2.96M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 12,839 | 11,218 | $2.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 9,949 | 8,974 | $1.91M |
| 59025 | Fetal non-stress test | 2.4% | 8,481 | 4,570 | $1.69M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 9,788 | 8,692 | $1.53M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.4% | 3,037 | 2,789 | $999K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 6,993 | 6,286 | $997K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 3,635 | 3,278 | $894K |
309 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 2,797 | $890K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 5,097 | $883K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,720 | $689K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,867 | $683K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,601 | $609K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,643 | $600K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,756 | $580K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,190 | $562K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 960 | $548K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 4,342 | $534K |
| 76830 | Ultrasound, transvaginal | <1% | 4,818 | $502K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,521 | $498K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,943 | $471K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,131 | $455K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,248 | $414K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,677 | $412K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,191 | $354K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,420 | $350K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 512 | $340K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,354 | $327K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,918 | $326K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,450 | $290K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,417 | $278K |
| 80053 | Comprehensive metabolic panel | <1% | 66,949 | $276K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 15,225 | $257K |
| 93976 | <1% | 3,063 | $255K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,552 | $251K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,086 | $251K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,310 | $244K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 689 | $237K |
| 93971 | <1% | 2,494 | $232K | |
| 76770 | <1% | 1,598 | $213K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,671 | $210K |
| 87400 | <1% | 17,228 | $193K | |
| 76536 | <1% | 1,464 | $180K | |
| 93970 | <1% | 1,331 | $175K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,099 | $174K |
| 76801 | <1% | 2,903 | $169K | |
| 97161 | <1% | 2,155 | $151K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,516 | $143K |
| 76642 | <1% | 1,249 | $141K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 717 | $140K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,262 | $135K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 989 | $133K |
| 72141 | <1% | 663 | $130K | |
| 12001 | <1% | 567 | $127K | |
| 70486 | <1% | 1,839 | $117K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,292 | $112K |
| 70496 | <1% | 432 | $109K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,960 | $102K |
| 71045 | Radiologic examination, chest; single view | <1% | 22,648 | $78K |
| 12011 | <1% | 342 | $77K | |
| 71250 | <1% | 1,193 | $74K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,892 | $73K |
| 77080 | <1% | 1,116 | $73K | |
| 74183 | <1% | 201 | $69K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,548 | $68K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 42,841 | $68K |
| 73564 | <1% | 4,571 | $59K | |
| 87420 | <1% | 3,529 | $56K | |
| 72110 | <1% | 2,506 | $55K | |
| 87040 | <1% | 9,191 | $55K | |
| 93017 | <1% | 600 | $54K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,763 | $50K |
| 74018 | <1% | 1,733 | $47K | |
| 84484 | <1% | 27,564 | $43K | |
| 73030 | <1% | 3,484 | $42K | |
| 72100 | <1% | 1,141 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,270 | $41K |
| 72131 | <1% | 721 | $40K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 492 | $38K |
| 97165 | <1% | 726 | $38K | |
| 70491 | <1% | 144 | $38K | |
| 83880 | <1% | 4,753 | $37K | |
| 90715 | <1% | 1,510 | $36K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 32,340 | $33K |
| 74174 | <1% | 161 | $32K | |
| 97162 | <1% | 332 | $32K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,169 | $31K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 68 | $30K |
| 73560 | <1% | 1,317 | $30K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,472 | $29K |
| 85379 | <1% | 4,944 | $29K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,940 | $27K |
| 73630 | <1% | 3,311 | $26K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,106 | $26K |
| J3490 | Unclassified drugs | <1% | 21,785 | $24K |
| 76870 | <1% | 309 | $24K | |
| 77066 | Tomosynthesis, mammo | <1% | 527 | $24K |
| 73130 | <1% | 2,540 | $22K | |
| 73610 | <1% | 2,950 | $22K | |
| 73221 | <1% | 83 | $21K | |
| 29125 | <1% | 119 | $20K | |
| 36430 | <1% | 107 | $20K | |
| 10060 | <1% | 126 | $20K | |
| 93798 | <1% | 159 | $18K | |
| 85027 | <1% | 9,418 | $18K | |
| 72050 | <1% | 683 | $17K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,178 | $17K |
| 73110 | <1% | 1,833 | $17K | |
| 77065 | Tomosynthesis, mammo | <1% | 340 | $17K |
| 96376 | <1% | 14,036 | $16K | |
| 94664 | <1% | 3,556 | $15K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,072 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,032 | $14K |
| 92526 | <1% | 392 | $14K | |
| 76820 | <1% | 486 | $14K | |
| 29105 | <1% | 65 | $13K | |
| 29515 | <1% | 54 | $13K | |
| 72040 | <1% | 343 | $13K | |
| 73501 | <1% | 1,069 | $12K | |
| 81001 | <1% | 31,710 | $12K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 154 | $12K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 415 | $12K |
| 70498 | <1% | 422 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,836 | $11K |
| 92610 | <1% | 165 | $11K | |
| 84702 | <1% | 16,151 | $10K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 457 | $10K |
| 84703 | <1% | 10,015 | $10K | |
| 80143 | <1% | 3,038 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 81 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,186 | $9K |
| 73140 | <1% | 1,047 | $9K | |
| 83605 | <1% | 6,125 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,394 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,385 | $9K |
| 73590 | <1% | 1,044 | $9K | |
| 87081 | <1% | 9,874 | $9K | |
| 85610 | <1% | 8,159 | $9K | |
| 80061 | Lipid panel | <1% | 2,758 | $8K |
| S0028 | Injection, famotidine, 20 mg | <1% | 5,278 | $8K |
| 74178 | <1% | 42 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,049 | $7K |
| 73620 | <1% | 277 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,800 | $7K |
| 73120 | <1% | 220 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,030 | $7K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $6K |
| 83735 | <1% | 8,080 | $6K | |
| 70544 | <1% | 29 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,504 | $6K |
| 76813 | <1% | 210 | $6K | |
| 83690 | <1% | 21,482 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,895 | $6K |
| 73080 | <1% | 859 | $5K | |
| 88304 | <1% | 420 | $5K | |
| 71101 | <1% | 611 | $5K | |
| 80179 | <1% | 2,997 | $5K | |
| 12002 | <1% | 24 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,250 | $5K |
| 97750 | <1% | 345 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,174 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,812 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,746 | $4K |
| 73502 | <1% | 226 | $4K | |
| 86850 | <1% | 3,913 | $4K | |
| 73700 | <1% | 41 | $4K | |
| 82248 | <1% | 2,770 | $4K | |
| 72128 | <1% | 108 | $4K | |
| 86900 | <1% | 5,615 | $4K | |
| 73090 | <1% | 622 | $4K | |
| 96367 | <1% | 759 | $4K | |
| 97166 | <1% | 16 | $3K | |
| 72070 | <1% | 125 | $3K | |
| 84439 | <1% | 679 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,291 | $3K |
| 87505 | <1% | 45 | $3K | |
| 76821 | <1% | 89 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 586 | $3K |
| 29130 | <1% | 13 | $3K | |
| 71271 | <1% | 31 | $3K | |
| 81003 | <1% | 9,039 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,034 | $2K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 8,563 | $2K |
| 87077 | <1% | 4,379 | $2K | |
| 84100 | <1% | 4,325 | $2K | |
| 82607 | <1% | 585 | $2K | |
| 86140 | <1% | 723 | $2K | |
| 85730 | <1% | 5,706 | $2K | |
| 85652 | <1% | 1,342 | $2K | |
| 84145 | <1% | 415 | $2K | |
| 87186 | <1% | 3,539 | $2K | |
| 86923 | <1% | 61 | $2K | |
| 86901 | <1% | 5,609 | $2K | |
| 82728 | <1% | 339 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 185 | $2K |
| 82247 | <1% | 325 | $2K | |
| 74019 | <1% | 73 | $1K | |
| 81025 | <1% | 4,527 | $1K | |
| 73600 | <1% | 97 | $1K | |
| 88342 | <1% | 570 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,330 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 457 | $1K |
| 73660 | <1% | 109 | $1K | |
| 97116 | <1% | 38 | $1K | |
| 82550 | <1% | 1,989 | $1K | |
| 87430 | <1% | 5,383 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,591 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,646 | $1K |
| 73100 | <1% | 60 | $1K | |
| 99292 | <1% | 469 | $988.17 | |
| 82570 | <1% | 735 | $966.92 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,391 | $937.50 |
| 90686 | <1% | 64 | $878.40 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 250 | $863.06 |
| C1769 | Guide wire | <1% | 1,070 | $859.77 |
| 73562 | <1% | 14 | $851.91 | |
| 72082 | <1% | 13 | $819.41 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,018 | $809.72 |
| 73060 | <1% | 119 | $807.92 | |
| G0008 | Administration of influenza virus vaccine | <1% | 108 | $798.15 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,006 | $773.58 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,064 | $768.27 |
| 83550 | <1% | 362 | $757.93 | |
| 83540 | <1% | 496 | $750.05 | |
| 87210 | <1% | 1,461 | $638.63 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 761 | $516.46 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,563 | $514.77 |
| 73552 | <1% | 102 | $500.94 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,688 | $452.04 |
| 87486 | <1% | 21 | $449.97 | |
| 84550 | <1% | 435 | $381.95 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,033 | $375.97 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,379 | $373.83 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,311 | $360.21 |
| 73070 | <1% | 16 | $357.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,637 | $348.74 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 887 | $334.09 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,684 | $309.47 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,061 | $297.99 |
| 84112 | <1% | 13 | $296.53 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,533 | $296.15 |
| 82805 | <1% | 1,166 | $295.70 | |
| 86780 | <1% | 38 | $281.39 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,235 | $271.46 |
| 87581 | <1% | 21 | $265.21 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,487 | $263.48 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 75 | $249.96 |
| 84156 | <1% | 374 | $220.62 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,854 | $200.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 923 | $197.99 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,092 | $180.74 |
| 87340 | <1% | 231 | $167.13 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 497 | $162.38 |
| 85018 | <1% | 344 | $159.32 | |
| 70360 | <1% | 14 | $158.05 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 886 | $152.33 |
| 86803 | <1% | 15 | $133.78 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 793 | $126.50 |
| 80076 | <1% | 32 | $122.96 | |
| 74022 | <1% | 18 | $117.48 | |
| 94760 | <1% | 1,736 | $116.46 | |
| 80047 | <1% | 15 | $109.98 | |
| 99152 | <1% | 543 | $107.57 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 654 | $90.49 |
| 87070 | <1% | 376 | $87.58 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 885 | $86.77 |
| J7999 | Compounded drug, not otherwise classified | <1% | 422 | $78.19 |
| 83615 | <1% | 302 | $74.66 | |
| 85014 | <1% | 131 | $68.62 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 255 | $64.38 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 856 | $60.87 |
| 82330 | <1% | 143 | $60.84 | |
| 80069 | <1% | 18 | $56.78 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 239 | $56.60 |
| 87205 | <1% | 350 | $54.60 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 220 | $54.23 |
| 72072 | <1% | 20 | $36.30 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,857 | $36.18 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 212 | $33.36 |
| 85007 | <1% | 115 | $29.58 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 581 | $24.66 |
| 99153 | Mod sedat endo service >5yrs | <1% | 270 | $24.64 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 282 | $23.66 |
| 87563 | <1% | 296 | $20.12 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 455 | $19.26 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 847 | $18.14 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 113 | $14.35 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 245 | $14.32 |
| 86141 | <1% | 13 | $12.35 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 310 | $11.48 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 58 | $6.37 |
| 87328 | <1% | 12 | $4.69 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 88 | $4.68 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 421 | $2.18 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 470 | $1.93 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 492 | $1.74 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 277 | $0.94 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,634 | $0.02 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 1,005 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 39 | $0.00 |
| 86308 | 0% | 239 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 199 | $0.00 |
| 74175 | 0% | 13 | $0.00 | |
| 36416 | 0% | 156 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 76 | $0.00 |
| 0259 | 0% | 265 | $0.00 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 19 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 55 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 31 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 187 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 188 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 307 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 45 | $0.00 |
| 82565 | 0% | 33 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 116 | $0.00 |
| 82272 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTALENTO, RICARDO (CORPORATE CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Inova Health Care Services | Falls Church, VA | $176.68M |
| Inova Health Care Services | Leesburg, VA | $46.97M |
| Inova Health Care Services | Alexandria, VA | $39.33M |
| Inova Health Care Services | Fairfax, VA | $33.53M |
| Inova Health Care Services | Springfield, VA | $8.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.